ATE493657T1 - Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs - Google Patents

Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs

Info

Publication number
ATE493657T1
ATE493657T1 AT04798043T AT04798043T ATE493657T1 AT E493657 T1 ATE493657 T1 AT E493657T1 AT 04798043 T AT04798043 T AT 04798043T AT 04798043 T AT04798043 T AT 04798043T AT E493657 T1 ATE493657 T1 AT E493657T1
Authority
AT
Austria
Prior art keywords
molecules
angiogenesis
jam
inhibiting
cancer
Prior art date
Application number
AT04798043T
Other languages
English (en)
Inventor
Beat Imhof
Michel Aurrand-Lions
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/738,123 external-priority patent/US7642341B2/en
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE493657T1 publication Critical patent/ATE493657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04798043T 2003-11-19 2004-11-19 Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs ATE493657T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03026629A EP1533617A1 (de) 2003-11-19 2003-11-19 Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs
US10/738,123 US7642341B2 (en) 2003-12-18 2003-12-18 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
PCT/EP2004/013247 WO2005050213A1 (en) 2003-11-19 2004-11-19 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer

Publications (1)

Publication Number Publication Date
ATE493657T1 true ATE493657T1 (de) 2011-01-15

Family

ID=34621557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798043T ATE493657T1 (de) 2003-11-19 2004-11-19 Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs

Country Status (18)

Country Link
US (1) US7790863B2 (de)
EP (2) EP1533617A1 (de)
JP (1) JP2007515159A (de)
KR (1) KR101135834B1 (de)
CN (1) CN1890567B (de)
AT (1) ATE493657T1 (de)
AU (1) AU2004291989B2 (de)
BR (1) BRPI0415541B8 (de)
CA (1) CA2546406C (de)
DE (1) DE602004030819D1 (de)
EA (1) EA009037B1 (de)
ES (1) ES2358905T3 (de)
IL (1) IL175686A (de)
MX (1) MXPA06005523A (de)
NO (1) NO20062793L (de)
SG (1) SG148190A1 (de)
WO (1) WO2005050213A1 (de)
ZA (1) ZA200603069B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01009110A (es) 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
AU2007301599B2 (en) * 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
CA2718092C (en) 2008-03-21 2019-03-19 Oncomethylome Sciences S.A. Detection and prognosis of cervical cancer
CN102333875B (zh) 2009-02-27 2014-04-16 诺华股份有限公司 选择表达异源蛋白质的真核细胞的方法
EP2670772B1 (de) 2011-02-02 2016-07-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Antagonisten von grasp55 zur verwendung als ein medikament
WO2012160031A1 (en) * 2011-05-24 2012-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for prognosing solid tumor outcome
CA2888345C (en) 2012-10-24 2020-04-21 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
GB201415367D0 (en) * 2014-08-29 2014-10-15 Iles Raymond K And Docherty Suzanne M E And Abban Thomas And Naase Mahmoud And Iles Jason K Methods for detecting abnormalities in haemoglobin
EP3277841A1 (de) * 2015-03-31 2018-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuer biomarker des ergebnisses bei aml
RU2599545C1 (ru) * 2015-11-06 2016-10-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации Способ подавления роста опухоли основе in vitro репрограммирования макрофагов на м1 фенотип с повышенной способностью к продукции оксида азота в эксперименте

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (de) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropes flüssig-kristallines segment-blockcopolymer
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0773288A3 (de) 1995-08-29 1997-07-09 Kirin Brewery Chimäre-Tier und dessen Verfahren zur Herstellung
EP0938505B1 (de) * 1996-05-31 2002-03-06 Health Research, Inc. Monoklonale Antikörper gegen Endoglin und ihre Verwendung in der anti-Angiogenese-Therapie
MXPA01009110A (es) * 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
AU2002315404A1 (en) * 2001-07-16 2003-03-03 Eli Lilly And Company Extracellular junctional adhesion molecules
US20030035802A1 (en) * 2001-08-14 2003-02-20 Dewan Zeng Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
EP1471938A4 (de) 2002-01-09 2008-03-05 Medarex Inc Menschliche monoklonale antikörper gegen cd30
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
IL175686A0 (en) 2006-09-05
EP1533617A1 (de) 2005-05-25
KR20060130562A (ko) 2006-12-19
IL175686A (en) 2012-02-29
US20070202110A1 (en) 2007-08-30
US7790863B2 (en) 2010-09-07
BRPI0415541B1 (pt) 2018-11-27
CN1890567B (zh) 2012-12-12
DE602004030819D1 (de) 2011-02-10
EP1685405A1 (de) 2006-08-02
BRPI0415541A (pt) 2006-12-26
SG148190A1 (en) 2008-12-31
CA2546406A1 (en) 2005-06-02
AU2004291989B2 (en) 2009-08-06
BRPI0415541B8 (pt) 2021-05-25
MXPA06005523A (es) 2006-12-14
ES2358905T3 (es) 2011-05-16
CN1890567A (zh) 2007-01-03
KR101135834B1 (ko) 2012-04-16
ZA200603069B (en) 2007-09-26
EA200600995A1 (ru) 2006-10-27
NO20062793L (no) 2006-08-18
HK1097908A1 (en) 2007-07-06
EA009037B1 (ru) 2007-10-26
JP2007515159A (ja) 2007-06-14
WO2005050213A1 (en) 2005-06-02
AU2004291989A1 (en) 2005-06-02
CA2546406C (en) 2013-04-09
EP1685405B1 (de) 2010-12-29

Similar Documents

Publication Publication Date Title
DE602004030819D1 (de) Angiogenesehemmende moleküle und ihre verwendung bei der behandlung und diagnose von krebs
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
EP2305716A3 (de) Antikörper gegen gpnmb und ihre verwendungen
EP2620450A3 (de) Antikörperzusammensetzungen gegen CTL4
EP3184539A3 (de) Psma antikörper
WO2005095457A3 (en) Immunoglobulins
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
WO2004083249A3 (en) Antibodies against human il-21 receptor and uses therefor
EP1572091A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
WO2010011999A3 (en) Methods and compositions for eliciting an amyloid-selective immune response
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2008045406A3 (en) COMPOUNDS, SCREENINGS, AND METHODS OF TREATMENT
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
WO2001073030A3 (en) Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2006036173A3 (en) Frizzled proteins and detection and treatment of cancer
ATE480641T1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
DE60216570D1 (de) Verfahren zum nachweis von alzheimer-krankheit
WO2007113685A3 (en) USE OF THE α CHAIN OF BRAIN SPECTRIN AND FRAGMENTS THEREOF, FOR DIAGNOSING CEREBRAL DISEASES
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
ATE547431T1 (de) Single-chain-antikörper gegen den 37 kda/67 kda lamininrezeptor als werkzeuge zur diagnose und therapie von prionerkrankungen und krebs, deren herstellung und verwendung
WO2002000939A3 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties